ZIM
UTHR icon

Zacks Investment Management’s United Therapeutics UTHR Stock Holding History

Zacks Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,457
Closed -$2.07M – 705
2022
Q4 		$2.07M Sell
7,457
-29
-0.4% -$7.32K 0.03% 273
2022
Q3 		$1.57M Buy
7,486
+93
+1% +$20.8K 0.03% 289
2022
Q2 		$1.74M Buy
+7,393
New +$1.5M 0.03% 273
2016
Q2 		– Sell
-2,327
Closed -$259K – 718
2016
Q1 		$259K Buy
+2,327
New +$294K 0.01% 522
2014
Q3 		– Sell
-5,237
Closed -$463K – 752
2014
Q2 		$463K Buy
5,237
+252
+5% +$24.2K 0.02% 460
2014
Q1 		$469K Buy
+4,985
New +$510K 0.02% 415

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Zacks Investment Management's UTHR Position: Q1 2023 in Review

Zacks Investment Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 7,457 shares — an estimated $2.07M sold.

Zacks Investment Management first reported a position in UTHR in Q1 2014 and held it in 6 quarters. The position peaked at $2.07M in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Zacks Investment Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Zacks Investment Management sold 7,457 United Therapeutics shares in Q1 2023, an estimated $2.07M.
  • Zacks Investment Management first reported a position in United Therapeutics in Q1 2014 and held it in 6 quarters.
  • Zacks Investment Management's United Therapeutics position peaked at $2.07M in Q4 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Zacks Investment Management's 13F filing for Q1 2023, filed 15 May 2023.